No Data
No Data
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates
Cartesian Therapeutics | 10-Q: Quarterly report
Cartesian Therapeutics 3Q Research and Development Expenses $11.4M >RNAC
Cartesian Therapeutics Reports Q3 EPS ($1.13) , Consensus (79c)
Earnings Flash (RNAC) CARTESIAN THERAPEUTICS Posts Q3 Revenue $387,000
Express News | Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
No Data
No Data